Endoscope-assisted Osseodensification Crestal Maxillary Sinus Floor Elevation Through Controlling The Tension Of Maxillary Sinus Mucosa

Prospective Cohort Study Of Endoscope-assisted Osseodensification Crestal Maxillary Sinus Floor Elevation Through Controlling The Tension Of Maxillary Sinus Mucosa

Status

Recruiting

Phases

Phase 1

Study type

Interventional

Source

ChiCTR

Registry ID

ChiCTR2300072248

Enrollment

Unknown

Registered

2023-06-07

Start date

2022-06-01

Completion date

Unknown

Last updated

2023-06-18

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

dentition partially missing

Interventions

RBH2-5mm,endoscope-assisted osseodensification crestal maxillary sinus floor elevation:RBH2-5mm

RBH5-8mm,endoscope-assisted osseodensification crestal maxillary sinus floor elevation:RBH5-8mm

RBH2-5mm,lateral sinus floor elevation:lateral sinus floor elevation

RBH5-8mm,osteotome technique sinus floor elevation:osteotome technique sinus floor elevation

Eligibility

Sex/Gender

All

Age

18 Years to 80 Years

Inclusion criteria

Inclusion criteria: (1)> 18 years old (2)maxillary posterior site edentulous for at least 3 months;(3)residual bone height: 2– 8mm with a double cortical bone structure ; (4) residual bone width: =6 mm ; (5)Bicortical bone structure; (6) good oral hygiene; (7) systemic and local conditions compatible with implant placement and sinus floor elevation procedures; and (8) willing and fully capable of complying with the study protocol

Exclusion criteria

Exclusion criteria: (1) diagnosis of maxillary sinusitis in the experimental quadrant and the existence of wide blood vessels, etc; (2)patients with less than 3 months of tooth extraction time;(3)There are stump roots in the missing tooth area;(4)Infection or abscess in the area adjacent to the operation;(5) untreated periodontal disease prior to implant placement; (6) patients with systemic disease, such as blood pressure above 180/100mmHg, fasting blood glucose above 8.8mmol/L, and severe cardiovascular disease;(7)patients with metabolic disorders;(8)patients taking drugs that affect bone healing, such as bisphosphonates, steroids, etc; (9) history of cigarette or alcohol abuse ;(10)history of radiation therapy in the head and neck area or chemotherapy

Design outcomes

Primary

Measure	Time frame
implant stability;sinus membrane perforations;	—

Secondary

Measure	Time frame
bone vertical augmentation;patient-reported outcomes;	—

Countries

People's Republic of China

Contacts

Public ContactTao Chen

Stomatological Hospital of Chongqing Medical University

chentao1985@hospital.cqmu.edu.cn+86 182 2502 9529

Outcome results

None listed

Source: ChiCTR (via WHO ICTRP) · Data processed: Feb 4, 2026